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Abstract 
Repeated activation of N-Methyl-D-aspartate receptors (NMDARs) causes a Ca
2+
-dependent 
reduction in NMDAR-mediated current in dopamine (DA) neurons of the substantia nigra 
pars compacta (SNc) in one week old rats; however, a Ca
2+
-dependent regulatory protein has 
not been identified. The role of the Ca
2+
-dependent cysteine protease, calpain, in mediating 
NMDAR current rundown was investigated. In brain slices from rats aged postnatal day 7-9 
(‘P7’), bath application of either of the membrane permeable calpain inhibitors, N-Acetyl-L-
leucyl-L-leucyl-L-norleucinal (ALLN, 20 M) or MDL-28170 (30 M) significantly reduced 
whole-cell NMDAR current rundown. To investigate the role of the calpain-2 isoform, the 
membrane permeable calpain-2 inhibitor, Z-Leu-Abu-CONH-CH2-C6H3 (3, 5-(OMe)2 (C2I, 
200 nM), was applied; C2I application significantly reduced whole cell NMDAR current 
rundown. Interestingly, ALLN but not C2I significantly reduced rundown of NMDA-EPSCs. 
These results suggest the calpain-2 isoform mediates Ca
2+
-dependent regulation of 
extrasynaptic NMDAR current in the first postnatal week, while calpain-1 might mediate 
rundown of synaptic NMDAR currents. One week later in postnatal development, at P12-P16 
(‘P14’), there was significantly less rundown in SNc-DA neurons, and no significant effect 
on rundown of either Ca
2+ 
chelation or treatment with the calpain inhibitor, ALLN, 
suggesting that the rundown observed in SNc-DA neurons from two week-old rats might be 
Ca
2+
-independent. In conclusion, Ca
2+
-dependent rundown of extrasynaptic NMDAR 
currents in SNc DA neurons involves calpain-2 activation, but Ca
2+
- and calpain-2-dependent 
NMDAR current rundown is developmentally regulated.  
 
 
 
 
 
 
 
 
3 
 
1. INTRODUCTION 
N-Methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors that play 
important roles in neuronal development and plasticity (Cull-Candy and Leszkiewicz, 2004; 
Luscher and Malenka, 2012; Paoletti et al., 2013; Traynelis et al, 2010; Wyllie et al., 2012). 
One important functional feature of NMDARs is their Ca
2+
 permeability, which results in 
activation of intracellular signalling pathways, including those that promote cell survival 
(Hardingham and Bading, 2010; Traynelis et al., 2010; Vyklicky et al., 2014). However, 
over-activity of NMDARs and the resulting excessive Ca
2+
 influx are also implicated in 
neuronal dysfunction and excitotoxicity through the activation of cell death signalling 
pathways (Choi, 1987; Hardingham and Bading, 2010; Surmeier et al., 2010). This 
mechanism could be a contributing factor to neurodegenerative diseases, such as 
Alzheimer’s, Huntington’s and Parkinson’s diseases (Parsons and Raymond, 2014; Ambrosi 
et al., 2014). 
NMDARs are themselves regulated by Ca
2+
-dependent processes, including a Ca
2+
-dependent 
reduction of NMDAR current, termed inactivation or rundown (Ehlers et al., 1996; Legendre 
et al., 1993; Rosenmund et al., 1995). NMDAR current rundown has previously been shown 
in substantia nigra pars compacta (SNc) dopaminergic (DA) neurons when NMDA was 
repetitively applied at an interval less than 400 s (Wild et al., 2014). Rundown was dependent 
on Ca
2+
 influx as it was reduced by increasing the concentration of intracellular buffer (from 
0.6 mM EGTA to 10 mM BAPTA), by replacing extracellular Ca
2+
 ions with Ba
2+
 ions, or by 
reducing the driving force for Ca
2+
 entry by depolarising the membrane potential to +40 mV 
(Wild et al., 2014). The Ca
2+
-dependent regulatory mechanism has not been identified. SNc 
DA neurons form a critical part of the basal ganglia circuitry involved in voluntary motor 
control (Hegarty et al., 2013), and their spiking is strongly influenced by glutamatergic inputs 
and NMDAR activity (Blythe et al., 2007; Jones et al., 2011). Degeneration of SNc-DA 
neurons is a pathological hallmark of Parkinson’s disease (Obeso et al., 2010; Beitz, 2014), 
and deregulated Ca
2+ 
influx is a possible contributing factor to DA neuronal death (Surmeier 
et al., 2010; 2011). Therefore, there is considerable interest in identifying the factors that 
regulate NMDAR activity in these and other brain neurons. 
Calpain is a Ca
2+
-dependent cysteine protease, which is activated upon NMDAR stimulation, 
and calpain is widely expressed in the mammalian central nervous system (Baudry and Bi, 
2016). Calpain has been shown to regulate NMDAR activity in synaptic membranes (Bi et 
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al., 1998) and over-activation of NMDARs results in a calpain-dependent suppression of 
NMDAR currents (Wu et al., 2005).  Calpain is also implicated in the pathophysiology of 
several neurological diseases such as traumatic brain injury and ischemia (Goll et al., 2003; 
Curcio et al., 2016). While 15 members have been identified in the calpain family (Sorimachi 
et al., 2010), the two major isoforms expressed in the brain are calpain-1 (µ-calpain) and 
calpain-2 (m-calpain) (Doshi and Lynch, 2009; Baudry and Bi, 2016). These two isoforms 
exhibit differing Ca
2+ 
sensitivity (micromolar versus milimolar concentrations of Ca
2+
 
respectively; Dayton, 1982), and recent studies have suggested that they play opposite 
functions in synaptic plasticity and neuronal death (Baudry and Bi, 2016). Calpain expression 
is also isoform-dependent, with calpain-1 being expressed in neuronal somata and calpain-2 
expressed in axonal processes and glial cells (Siman et al., 1985). Furthermore, higher levels 
of calpain are found in hindbrain and midbrain structures compared with forebrain structures 
in rats (Simonson et al., 1985). Calpain is present in SNc-DA neurons in the adult rat (Siman 
et al., 1985), although in human post-mortem brains, calpain-2 was detected only in the 
substantia nigra of Parkinsonian (PD) patients, not in control subjects (Mouatt-Prigent et al., 
1996), raising the possibility that calpain-2 might be upregulated in PD. In this study, the role 
of calpain in Ca
2+
-dependent NMDAR current rundown in SNc-DA neurons was investigated 
using two inhibitors that target both of these calpain isoforms (ALLN and MDL-28170) and 
one inhibitor more selective for the calpain-2 isoform, Z-Leu-Abu-CONH-CH2-C6H3 (3, 5-
(OMe)2 (C2I) (Wang et al., 2014), and a significant reduction in NMDAR current rundown 
was observed. 
 
2. MATERIALS AND METHODS 
Wistar rats (Charles River) aged postnatal day 7-16 were used in all experiments in 
accordance with the Animals (Scientific procedures) Act 1986 and with the University of 
Cambridge Animal Welfare and Ethical Review Board. Animals were housed in 12 hour 
light/dark cycle with up to 8 pups per dam and ad libitum access to food and water.  Rats 
were anesthetized with isofluorane, then decapitated and brains were removed and submerged 
in ice-cold solution containing (mM): NaCl 52.5, sucrose 100, KCl 2.5, NaH2PO4 1.25, 
NaHCO3 26, glucose 25, MgCl2 5, CaCl2 1, kynurenic acid 0.1; pH 7.4 with 95% O2/5% CO2. 
Horizontal slices (250 – 300 µm) containing the substantia nigra were made using a Campden 
7000smz Vibrating Microtome (Campden Instruments, UK). Slices were then transferred to 
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an incubation chamber containing (mM): NaCl 119, KCl 2.5, NaH2PO4 1.25, NaHCO3 26, 
glucose 25, MgCl2 5, CaCl2 2 at 30 °C, saturated with 95% O2 and 5% CO2, and left 
undisturbed for 45 minutes to 5 hours. 
Brain slices were transferred to a recording chamber and perfused at 2-3mL/min with 
oxygenated solution (as stated above except with 10 mM glucose and 0.1 mM MgCl2) at 30 ± 
2 °C. In some experiments, no CaCl2 was added to the recording solution and instead 2 mM 
BaCl2 was added (nominally Ca
2+
-free solution). Patch pipettes with a tip resistance of 1.5-
3.5MΩ were filled with intracellular solution containing (mM): CsMeSO3 120, CsCl 5, NaCl 
2.8, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 20, MgCl2 3, CaCl2 0.5, 
Mg-ATP (adenosine triphosphate) 2, Na-GTP (guanine triphosphate) 0.3, Ethylene glycol-
bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) 0.6, EGTA 10 or 1,2-Bis(2-
aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester) (BAPTA) 10, 
as indicated in the text (pH 7.2-3, 270-290 mOsm). Series resistance was measured between 
each agonist application and was typically 3-5 M; recordings were discarded if the series 
resistance was unstable. SNc-DA neurons were identified by visually locating the medial 
terminal nucleus of the accessory optic tract. DA neurons make up ~90% of the SNc neuronal 
population and exhibit a time-dependent, hyperpolarization-activated inward current (Ih) (of 
more than 50 pA) following a voltage step from -60 to -120 mV (Margolis et al., 2006; Wild 
et al., 2014; Neuhoff et al., 2002; Washio et al., 1999).  
SNc-DA neurons were voltage clamped to -60 mV, -50 mV or +40 mV (as indicated in the 
text) using an Axopatch 200B patch clamp amplifier (Molecular Devices, USA). Whole-cell 
currents were elicited by agonist applications (NMDA 0.5 mM; 5 s in duration; 100 s 
interval; 10 psi) via a Picospritzer II (General Valve corporation), positioned ~200 µm away 
from the cell, in the presence of picrotoxin 50 µM, glycine 10 µM and tetrodotoxin (TTX) 
100 nM. Application via the picospritzer results in ~50% dilution to ~250 µM NMDA (Wild 
et al., 2013). Synaptic NMDARs were stimulated using a bipolar stainless steel electrode 
(Frederick Haer and Co., USA); stimuli (100 s duration, amplitude 60 to 250 A) were 
applied every 10 s in the presence of picrotoxin (50 M), glycine (10 µM) and DNQX (10 
µM). Drugs were applied to the perfusion solution immediately after the visualization of the 
Ih; the first NMDA application occurred at least 300 s after drug application.  
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Data were recorded and analysed using Spike 2 software (Version 4; Cambridge Electronic 
Design, Cambridge, UK). To quantify the extent of rundown, peak current amplitude in 
response to electrical stimulation or agonist application was measured. The ratio of the 
average NMDAR-EPSC recorded at 500-600 s to the average NMDAR-EPSC at 0-100 s 
(It500-600s/It(0-100s), or the ratio of the last agonist-induced response to the first response 
(It300/It0) was calculated. Statistical analyses were carried out using GraphPad Prism (version 
4.0, La Jolla California, USA). Data distribution was assessed using the Shapiro Wilk 
Normality test. When comparing two groups of paired or unpaired data, the paired or 
unpaired Student’s t-test or a non-parametric test were used. For more than two groups of 
data, one-way ANOVA with Tukey’s post-tests were used. Data are expressed as mean ± 
standard error (SE), and ‘n’ values indicate the number of cells, which is equivalent to the 
number of slices.  
 
3. RESULTS 
3.1 Repeated agonist application leads to Ca
2+
-dependent NMDAR current rundown 
NMDAR current rundown was confirmed in SNc-DA neurons from P7-P9 (‘P7’) rats by four 
consecutive agonist applications. Neurons were voltage clamped to -60 mV with the Ca
2+
 
chelator EGTA (0.6 mM) in the intracellular pipette solution. Under these conditions, the 
peak inward current decreased in amplitude after the first agonist application (Figure 1A, B, 
E). The initial current response to NMDA application (It0) had a mean amplitude of 1657 ± 
278 pA, while the fourth response (It300) was significantly reduced, with a mean amplitude of 
785 ± 110 pA (n = 16 cells from 15 rats; P = 0.0005; Wilcoxon signed rank test; Figure 1B). 
Rundown was not significantly different in the presence of CdCl2 (200 M; 0.53 ± 0.11, n = 
4 cells from 4 rats; P = 0.96, Mann Whitney test), which blocks voltage-gated Ca
2+
 channels 
(Lansman et al., 1986).  
Previously, two mechanisms were suggested to regulate NMDAR rundown in SNc-DA 
neurons: Ca
2+
-independent receptor trafficking and an unidentified Ca
2+
-dependent process 
(Wild et al., 2014). In order to confirm the Ca
2+
-dependence of rundown, the individual 
conditions that previously caused a reduction in rundown were combined: DA neurons were 
voltage-clamped to +40 mV to reduce the driving force for Ca
2+
 influx, EGTA in the 
intracellular pipette solution was replaced with the more rapid Ca
2+
 chelator BAPTA, at a 
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higher concentration (10 mM), and extracellular Ca
2+
 was replaced with an equal 
concentration of Ba
2+
 (nominally Ca
2+
-free solution). Under these conditions, there was still a 
significant rundown; mean It0 was 3162 ± 659 pA and mean It300 was 2552 ± 561 pA (Figure 
1C, D; n = 7 cells from 7 rats; t(6) = 3.73; P = 0.01, paired t-test test). However, the extent of 
rundown was smaller: the ratio of It300 / It0 in Ca
2+
 /EGTA/-60 mV was 0.52 ± 0.04 (n = 16) 
while in Ba
2+
 /BAPTA/+40 mV, It300/It0 was 0.8 ± 0.04 (n = 7; t(21) = 3.97; P = 0.0007, 
unpaired t- test; Figure 1E). This is in agreement with Wild et al. (2014) who showed that 
NMDAR current rundown is at least partially dependent on an increase in intracellular [Ca
2+
] 
due to Ca
2+
 influx. The most likely source of Ca
2+
 influx is via the NMDAR. The difference 
in rundown between Ca
2+
 /EGTA/-60 mV versus Ba
2+
 /BAPTA/+40 mV could be explained 
either by the difference in the concentration of Ca
2+
 buffer used, or by the faster kinetics of 
Ca
2+
 binding to BAPTA as compared with EGTA. To explore this, rundown was measured in 
recordings in nominally Ca
2+
-free solution with Ba
2+
 /10 mM EGTA/+40 mV (n = 7 cells 
from 5 rats); the time course of rundown fell between that for the other two conditions 
(Figure 1F), suggesting that both the concentration of the buffer and the kinetics of buffering 
influence Ca
2+
-dependent rundown.   
3.2 Calpain inhibition reduces NMDAR current rundown 
Inhibition of Ca
2+
/calmodulin,  α-actinin depolymerisation, or  calcineurin did not prevent 
NMDAR current rundown in SNc-DA neurons (Wild et al., 2014). Calpain is another 
calcium-dependent signalling molecule that has been shown to modulate NMDAR current 
rundown in cortical neurons (Bi et al., 2000, 1998; Wu et al., 2005). To investigate whether 
calpain mediates Ca
2+
-dependent NMDAR current rundown in SNc-DA neurons, the 
membrane permeable calpain inhibitor N-Acetyl-L-leucyl-L-leucyl-L-norleucinal (ALLN, 20 
µM) was applied to the perfusion solution during recordings (Figure 2A, B, D). The mean It0 
in the presence of ALLN was 1229 ± 130 pA, while the mean It300 was 1075 ± 185 pA (n = 9 
cells from 7 rats); there was no significant difference between It0 and It300 in ALLN (t(8) = 
1.44; P = 0.19, paired t-test). There was an overall significant effect of ALLN treatment on 
the extent of NMDAR current rundown (F(2, 30) = 7.99; P = 0.0017; one way ANOVA); post-
hoc comparisons showed that there was significantly less rundown in ALLN (average It300/It0 
= 0.85 ± 0.09; n = 9) compared to the DMSO vehicle (2:1000; It300/It0 = 0.50 ± 0.07; n = 8 
cells from 5 rats; P < 0.001, Tukey’s Multiple Comparison test; Figure 2E). The time of the 
first application of NMDA was 458 ± 53 s after forming the whole-cell configuration, which 
was not significantly different to the time of the first response in control recordings (465 ± 
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78, n = 16; P = 0.95, unpaired t-test). There was no significant effect of DMSO alone on 
rundown (P > 0.05, Tukey’s Multiple Comparison test; Figure 2E).  
Application of a second membrane permeable calpain inhibitor, MDL-28170 (30 µM) had an 
overall significant effect on rundown (F(2, 29) = 4.72; P = 0.017; one-way ANOVA; Figure 
2C, D, F). Post-hoc comparisons showed that rundown was significantly reduced in MDL-
28170 (It300/It0 = 0.76 ± 0.1; n = 9 cells from 6 rats) compared to application of vehicle 
solution (3:1000 DMSO; It300/It0 = 0.47 ± 0.05; n = 7 cells from 6 rats; P < 0.05, Tukey’s 
Multiple Comparison test). The time of the first application of NMDA was 640 ± 34 s after 
forming the whole-cell configuration, which was not significantly different to the time of the 
first response in control recordings (465 ± 78, n = 16; P = 0.12, unpaired t-test). 
3.3 Calpain-2 inhibition reduces NMDAR current rundown 
Two calpain isoforms (calpain-1 and calpain-2) are ubiquitously expressed in the mammalian 
brain (Doshi and Lynch, 2009; Baudry and Bi, 2016). To investigate which calpain isoform 
might be responsible for Ca
2+
-dependent NMDAR current rundown, a membrane permeable 
inhibitor selective for calpain-2 (Z-Leu-Abu-CONH-CH2-C6H3(3,5-(OMe)2) or C2I, 200 nM) 
was applied. The mean It0 in the presence of C2I (200 nM) was 1238 ± 222 pA, while the 
mean It300 was 836 ± 202 pA (n = 11 cells from 9 rats; Figure 3A, B); there was no significant 
difference between It0 and It300 (t(10) = 1.52; P = 0.32, paired t-test). There was an overall 
significant effect of C2I treatment on the extent of NMDAR current rundown (F(2,32) = 6.94; 
P = 0.003; one way ANOVA); post-hoc comparisons showed that there was significantly less 
rundown in C2I (average It300/It0 = 0.90 ± 0.12; n = 11) compared to the DMSO vehicle 
(2:1000; It300/It0 = 0.50 ± 0.07; n = 8 cells from 5 rats; P < 0.001, Tukey’s Multiple 
Comparison test; Figure 3D). The time of the first application of NMDA was 564 ± 27 s after 
forming the whole-cell configuration, which was not significantly different to the time of the 
first response in control recordings (465 ± 78; P = 0.32, unpaired t-test). This finding 
suggests that the Ca
2+
-dependent rundown of whole-cell NMDARs in SNc-DA neurons from 
P7 rats is mediated by calpain-2. 
3.4 Ca
2+
- and calpain-dependent NMDAR current rundown is developmentally regulated 
To determine whether rundown is developmentally regulated, experiments were carried out in 
SNc-DA neurons from rats aged P12-P16 (‘P14’). Significant rundown was observed in SNc-
DA neurons from P14 rats in Ca/EGTA/-60mV (from 1722 ± 256 pA at It0 to 1071 ± 88 pA at 
It300; n = 14 cells from 12 rats; t(13) = 3.1; P = 0.0006; paired t-test; example shown in Figure 
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4A). However, the extent of rundown was significantly less than that seen in SNc-DA 
neurons from P7 rats (Figure 4B; t(28) = 2.64; P = 0.014, unpaired t-test). In SNc-DA neurons 
from P14 rats, there was no significant effect of replacing Ca
2+
 /EGTA/-60mV with Ba
2+
 
/BAPTA/+40mV (n = 6 cells from 6 rats; t(18) = 0.97; P = 0.34, unpaired t-test; Figure 4C). 
Concomitantly, ALLN (20 M; n = 5 cells from 5 rats) had no significant effect on NMDAR 
current rundown in SNc-DA neurons from P14 rats (t(17) = 0.123; P = 0.90, unpaired t-test; 
Figure 4D, E). These results suggest that Ca
2+
- and calpain-dependent NMDAR current 
rundown is developmentally regulated between the first and second postnatal week. 
 
3.5 Calpain inhibition reduces synaptic NMDAR current rundown 
NMDAR-EPSCs in SNc-DA neurons were previously shown to rundown over a similar time 
course to whole-cell NMDAR current rundown (Wild et al., 2014). To determine whether 
rundown of synaptic NMDARs is also regulated by calpain, NMDAR-EPSCs were recorded 
at -50 mV in 0.1 mM MgCl2, 50 M picrotoxin, 10 M glycine and 10 M DNQX, using 0.6 
mM EGTA as the Ca
2+
 chelator and Ca
2+
 as the charge carrier. In control recordings, the 
NMDAR-EPSC mean amplitude at t0-100s was -40 ± 11.6 pA (n = 7 cells from 7 rats); this was 
significantly reduced at t500-600s (22.4 ± 8.2 pA, n = 7; t(6) = 3.35; P = 0.015, paired t-test; 
Figure 5A, B). In the presence of ALLN (20 M), NMDAR-EPSC mean amplitude at t0-100s 
was -34.5 ± 5.2 pA (n = 7 cells from 7 rats); this was not significantly different at t500-600s 
(35.1 ± 6.0 pA, n = 7; P = 0.94, Wilcoxon signed rank test; Figure 5C, D). In the presence of 
C2I (200 nM), the mean NMDAR-EPSC amplitude at t0-100s was -30.6 ± 4.1 pA (n = 7 cells 
from 7 rats); this was significantly reduced at t500-600s (18.1 ± 2.3 pA, n = 7; t(6) = 5.16; P = 
0.002, paired t-test). The time course of NMDAR-EPSC rundown in control, DMSO 
(2/1000), ALLN and C2I is shown in Figure 5E. Rundown, quantified as the ratio of t500-
600s/t0-100s (Figure 5F), was significantly less in ALLN (1.0 ± 0.06) than in control (0.54 ± 
0.11; P < 0.01), C2I (0.61 ± 0.04; P < 0.05), or DMSO (0.67 ± 0.1; P < 0.05); Tukey’s 
Multiple Comparisons test following one way ANOVA (F(3, 28) = 5.9; P = 0.003). These 
results suggest that calpain-1 activation but not calpain-2 activation participates in rundown 
of synaptic NMDAR currents. 
 
4. DISCUSSION 
Activity- and Ca
2+
-dependent regulation, such as rundown of NMDAR currents is a potential 
mechanism to limit excessive Ca
2+
 influx and might serve a neuroprotective role under 
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excitotoxic conditions. Several regulatory mechanisms responsible for Ca
2+
-dependent 
NMDAR current rundown have been identified in hippocampal and cortical neurons. 
NMDARs can bind signal transduction molecules via the C-termini of their subunits and this 
can alter NMDAR number, distribution and activity at the plasma membrane (Lin et al., 
2004; Petralia et al., 2009; Salter et al., 2009). Ca
2+
-dependent proteins regulating NMDARs 
include serine/ threonine kinases and phosphatases; for example, application of Ca
2+
 and 
CaM reduced single channel activity in HEK cells expressing GluN1/GluN2A receptors 
(Krupp et al., 1999). However, in SNc-DA neurons, inhibitors of serine/ threonine kinases 
and phosphatases had no effect on NMDAR current rundown (Wild et al., 2014). 
Another Ca
2+
-dependent mechanism regulating receptor function consists of the activation of 
calpain, a Ca
2+
-dependent cysteine protease. Calpain is activated by NMDAR-mediated Ca
2+
 
influx and can in turn regulate NMDAR activity (Bi et al., 1998; Wu et al., 2005). Whole-cell 
NMDAR current rundown in SNc-DA neurons was reduced in the presence of two broad 
spectrum calpain inhibitors (ALLN and MDL-28170) and by a more selective inhibitor of the 
calpain-2 isoform, implicating calpain-2 as the Ca
2+
-dependent mechanism involved in 
whole-cell NMDAR current rundown in SNc-DA neurons. Interestingly, synaptic NMDAR 
rundown was also reduced by the broad spectrum calpain inhibitor, ALLN, but not by the 
calpain-2 inhibitor. Extrasynaptic NMDAR currents are more likely to be assessed in whole-
cell recording, suggesting that different calpain isoforms regulate rundown of synaptic versus 
extrasynaptic NMDAR currents. Extrasynaptic NMDAR stimulation could lead to calpain-2 
activation through the stimulation of ERK and the phosphorylation of Ser 50 of calpain-2 
(Baudry and Bi, 2016). In contrast, it was previously shown that activation of synaptic 
NMDARs, but not extrasynaptic NMDARs results in recruiting of calpain-1 to NMDARs 
(Wang et al., 2013). This could account for the selective rundown of synaptic NMDARs by 
calpain-1. As increased levels of calpain-2 have specifically been associated with SNc-DA 
neurons exhibiting pathology in post-mortem brains of PD but not control patients (Mouatt-
Prigent et al., 1996), it is possible that increased calpain-2 expression represents a 
neuroprotective mechanism to autoregulate extracellular NMDAR-mediated Ca
2+
 influx 
when this becomes pathologically high. 
Although calpain activity resulted in reduced NMDAR current, rundown was not completely 
blocked by calpain inhibition. It is possible that other Ca
2+
-binding proteins contribute to 
rundown, alongside calpain. For example, calbindin inhibits Ca
2+
-dependent rundown of 
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NMDARs expressed in HEK-293 cells (Price et al., 1999). However, the remaining rundown 
is likely to be Ca
2+
-independent, as dynamin inhibition has been shown to block a component 
of rundown in SNc-DA neurons (Wild et al., 2014). Ca
2+
-independent rundown is also likely 
to account for the rundown observed during recordings at +40 mV, to reduce the driving 
force for Ca
2+
 influx, and in nominally Ca
2+
-free solution (using Ba
2+
 as the charge carrier), 
with either 10 mM EGTA or 10 mM BAPTA. Some Ca
2+
 influx may still occur under these 
conditions, but the rundown of 20-30% seen under these conditions is consistent with the 
Ca
2+
-independent rundown reported by Wild et al. (2014). 
What might be the downstream mechanism by which calpain effects rundown? Studies have 
shown that the C-terminal domains (CTD) of NMDARs may be important, as deletion of the 
GluN1 CTD eliminates Ca
2+
-dependent NMDAR inactivation (Ehlers et al., 1996). Calpains 
have been shown to interact directly with NMDARs and cleave the CTD of GluN2A, 2B, and 
2C subunits (Doshi and Lynch, 2010; Guttmann et al., 2001). It is possible that a similar 
mechanism exists in SNc-DA neurons, such that the proteolysis of NMDAR subunits by 
calpain could result in decreased NMDAR activity and/or decreased NMDAR surface 
expression, thereby reducing currents from subsequent NMDAR stimulation. This hypothesis 
could account for the lack of reversibility of the NMDAR rundown (Wild et al, 2014). 
Evidence suggests that GluN2A subunits do not contribute to functional synaptic or 
extrasynaptic NMDARs in postnatal SNc-DA neurons (Brothwell et al., 2008; Jones and 
Gibb, 2005; Suarez et al., 2010) and GluN2C subunits are not expressed at detectable levels 
(Hallett and Standaert, 2004). However, calpains have been shown to exhibit selectivity in the 
degradation of GluN2B over GluN2A subunits (Araújo et al., 2005; Simpkins et al., 2003). It 
was previously shown that, after inhibiting the GluN2B component of whole-cell NMDAR 
current using ifenprodil, the remaining component (presumed to be GluN2D-mediated) does 
not show Ca
2+
-dependent rundown (Wild et al., 2014). Therefore, it is likely that in SNc-DA 
neurons calpain would act on GluN2B subunits. Interestingly, neighbouring DA neurons of 
the ventral tegmental area (VTA) express GluN2A as well as GluN2B subunits (Borgland et 
al., 2006); as VTA DA neurons also express calpain (Liu et al., 2007; Mouatt-Prigent et al., 
1996), it is likely that NMDARs in VTA DA neurons are a target for Ca
2+
- and calpain-
dependent regulation. It would be interesting to compare calpain regulation of NMDARs and 
its potential neuroprotective role in VTA versus SNc DA neurons. 
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Studies on substrates specific for the two major calpain isoforms (calpain-1 and calpain-2) 
are scarce, but calpain-1 and calpain-2 have different PDZ binding motifs and have been 
suggested to associate with distinct protein clusters (Baudry and Bi, 2016). For example, it 
has been shown that calpain-1 selectively associates with NMDAR multiprotein complexes 
and co-immunoprecipitates with PSD-95 and GluN2A subunits after synaptic activation 
(Wang et al., 2013). This finding supports the idea that calpain-1 is generally associated with 
synaptic NMDARs, and the lack of effect of calpain-2 inhibition on NMDA-EPSCs would 
support this idea. On the other hand, NR2B subunits directly bind RasGRF1, which provides 
a link between NMDAR activation and ERK (Krapivinsky et al., 2003), and the resulting 
calpain-2 activation. Inhibition of calpain-2 reduced striatal enriched protein tyrosine 
phosphatase 61 (STEP61) cleavage and cell death after extrasynaptic NMDAR activation 
(Wang et al., 2013). Therefore, calpain-2-mediated regulation of extrasynaptic NMDAR 
rundown in SNc-DA neurons could represent a negative feed-back providing a 
neuroprotective process under excitotoxic conditions.  
NMDARs of SNc-DA neurons are proposed to undergo a developmental transition from 
GluN1/GluN2B and GluN1/GluN2D-containing diheteromeric receptors to GluN1/ GluN2B/ 
GluN2D containing triheteromeric receptors (Brothwell et al., 2008; Suárez et al., 2010). 
This transition occurs between P7 and P14 and affects receptor properties such as decay 
kinetics and sensitivity to Mg
2+ 
block. NMDAR current rundown was measured during the 
second week of postnatal development, and was present but reduced in amplitude, as 
compared with the first postnatal week. This seems likely to be due to a reduction of Ca
2+
- 
and calpain-dependent rundown, as conditions to minimise an increase in intracellular Ca
2+
 or 
to inhibit calpain activity had no significant effect on rundown in slices from P14 rats. It is 
plausible that calpain activity is reduced between P7 and P14, as a decrease in calpain-2 
activity has been reported during postnatal development (Simonson et al., 1985). This raises 
the interesting possibility that calpain-2 is down-regulated during postnatal development, but 
up-regulated under various pathological conditions, including PD (Mouatt-Prigent et al., 
1996). Alternatively, a change in NMDAR subunit composition between P7 and P14, from 
predominantly GluN1/GluN2B and GluN1/GluN2D diheteromeric receptors to putative 
GluN1/GluN2B/GluN2D triheteromeric receptors (Brothwell et al., 2008; Suarez et al., 
2010), may render NMDAR less susceptible to current rundown; in support of this, there was 
significantly less rundown of the ifenprodil-insensitive NMDAR current (Wild et al., 2014).  
These are all important considerations, as developing SNc-DA neurons may be losing a 
13 
 
neuroprotective effect provided by calpain-2 and may as a result become more vulnerable to 
excitotoxic insult. However, the possibility that both Ca
2+
-dependent and Ca
2+
-independent 
rundown were concurrently reduced during early postnatal development, rather than a 
specific reduction only in Ca
2+
-dependent rundown, cannot currently be ruled out. 
In conclusion, these results implicate calpain-2 in the Ca
2+
-dependent regulation of 
extrasynaptic NMDARs and calpain-1 in the Ca
2+
-dependent regulation of synaptic 
NMDARs in SNc-DA neurons during the first postnatal week and suggest that these roles of 
calpain-1 and calpain-2 are developmentally regulated.  
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Figure legends 
Figure 1:  Repeated agonist application induces Ca
2+
-dependent NMDAR current 
rundown in P7 rats 
A. Example current recorded from a SNc-DA neuron voltage-clamped to -60 mV with 0.6 
mM EGTA in the intracellular solution. NMDA was applied for 5 s at 100 s intervals 
(arrows). Deflections in the trace indicates series resistance checks.  B. Graph showing the 
initial (t0s) and final (t300s) current amplitude for all experiments in Ca/EGTA/-60mV (n = 16; 
***P = 0.0005, Wilcoxon signed rank test). C. Example current recorded from a SNc-DA 
neuron voltage-clamped to +40 mV with Ca
2+
 replaced by Ba
2+ 
in the extracellular solution 
and 10 mM BAPTA in the intracellular solution. D. Graph showing the initial (t0s) and final 
(t300s) current amplitude for all experiments in Ba/ BAPTA/ +40mV (n = 7; P = 0.01, paired t-
test). E. Rundown was significantly less in Ba/ 10 mM BAPTA/ +40mV than in Ca/ 0.6 mM 
EGTA/ -60mV. ***P = 0.007, paired t-test. F. Time-course of rundown with either 
Ca/0.6mM EGTA/-60mV, Ba/10mM EGTA/+40mV or Ba/10mM BAPTA/+40mV. 
 
Figure 2: Calpain inhibition reduces NMDAR current rundown in P7 rats 
A. Example current recorded from a SNc-DA neuron voltage-clamped to -60 mV with 0.6 
mM EGTA in the intracellular solution and ALLN (20 M) in the perfusion. NMDA was 
applied for 5 s at 100 s intervals (arrows).  B. Graph showing the amplitude of NMDAR 
currents at t0s and t300s for all experiments recorded in ALLN (n = 9; P = 0.19). C. Example 
current recorded from a SNc-DA neuron voltage-clamped to -60 mV with 0.6 mM EGTA in 
the intracellular solution and MDL-28170 (30 M) in the perfusion. NMDA was applied for 
5 s at 100 s intervals (arrows).  D. Time course of rundown with either control, DMSO, 
ALLN or MDL in the perfusion (Ca/0.6 EGTA/-60mV). E. Comparison of initial and final 
mean current amplitude in DMSO (n = 8), control (n = 16) or ALLN (n = 9; **P < 0.01, 
Tukey’s Multiple Comparison test). F. Comparison of initial and final mean current 
amplitude in DMSO (n = 7), control (n = 16) and MDL (n = 9). *P < 0.05, Tukey’s Multiple 
Comparison test. 
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Figure 3: Calpain-2 inhibition reduces rundown in P7 rats 
A. Example current recorded from a SNc-DA neuron voltage-clamped to -60 mV with 0.6 
mM EGTA in the intracellular solution and calpain-2 inhibitor (C2I, 200 nM) in the 
perfusion. NMDA was applied for 5 s at 100 s intervals (arrows). B. Graph showing the 
amplitude of NMDAR currents at t0s and t300s for all experiments recorded in C2I (n = 11; P = 
0.16). C. Time course of rundown in control, DMSO (2/1000) or C2I. D. Comparison of 
initial and final mean current amplitude in control (n = 16), DMSO (n = 8) or C2I (n = 9). *P 
< 0.05, **P < 0.01, Tukey’s Multiple Comparison test. 
 
 
Figure 4:  Ca
2+
- and calpain-dependent NMDAR current rundown in P14 rats 
A. Example current recorded from a SNc-DA neuron voltage-clamped to -60 mV with 0.6 
mM EGTA in the intracellular solution. NMDA was applied for 5 s at 100 s intervals 
(arrows). B. There was significantly less NMDAR current rundown in SNc-DA neurons from 
P14 rats compared with P7 rats (in Ca/EGTA/-60mV; *P = 0.014, unpaired t-test). C. There 
was no significant difference in rundown in Ba/ BAPTA/+40mV (n = 6) compared with Ca/ 
EGTA/-60mV (n = 14) in P14 animals (P = 0.35, unpaired t-test). D. Example current 
recorded from a SNc-DA neuron voltage-clamped to -60 mV with 0.6 mM EGTA in the 
intracellular solution and ALLN (20 M) in the perfusion. NMDA was applied for 5 s at 100 
s intervals (arrows). E. Application of ALLN (n = 5) had no significant effect on NMDAR 
current rundown at P14 compared with control (n = 14; P = 0.90, unpaired t-test). 
 
 
Figure 5: Calpain inhibition reduces synaptic NMDAR current rundown in P7 rats 
A. Example NMDAR-EPSCs recorded from a SNc-DA neuron voltage-clamped to -50 mV 
with 0.6 mM EGTA in the intracellular solution. B. Graph showing the initial (t0-100s) and 
final (t500-600s) NMDAR-EPSC mean amplitude for all experiments in Ca/EGTA/-60mV (n = 
7; *P = 0.015, paired t-test). C. Example NMDAR-EPSCs recorded from a SNc-DA neuron 
voltage-clamped to -50 mV with 0.6 mM EGTA in the intracellular solution and ALLN (20 
M) in the perfusion. D. Graph showing the initial (t0-100s) and final (t500-600s) NMDAR-EPSC 
amplitude for all experiments in Ca/EGTA/-60mV with ALLN in the perfusion (n = 7; P = 
0.93, Wilcoxon signed rank test). E. Example NMDAR-EPSCs recorded from a SNc-DA 
neuron voltage-clamped to -50 mV with 0.6 mM EGTA in the intracellular solution and C2I 
16 
 
(200 nM) in the perfusion. F. Graph showing the initial (t0-100s) and final (t500-600s) NMDAR-
EPSC amplitude for all experiments in Ca/EGTA/-60mV with C2I in the perfusion (n = 7; P 
= 0.002, paired t-test). G. Time-course of NMDAR-EPSC rundown with either control, 
DMSO (2/1000), ALLN (20 M) or C2I (200 nM). H. Rundown was significantly less in 
ALLN than in control (**P < 0.01) or DMSO/ C2I (*P < 0.05; ANOVA and Tukey’s 
Multiple Comparison test). 
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